The most significantly dysregulated gene CEP135 was further discovered to be used as a novel biomarker that stratifies sarcoma patients with better and poor survival outcomes among the TCGA database of 33 various cancer types (Fig. 1). This evidence concerns the gene CEP135 and cancer.